Protocol for the Study of Heart and Renal Protection-Extended Review
Additional 5-Year Follow-up of the Australian, New Zealand, and Malaysian SHARP Cohort
Sukkar, Louisa; Talbot, Ben; Jun, Min; Dempsey, Erika; Walker, Robert; Hooi, Lai; Cass, Alan; Jardine, Meg; Gallagher, Martin
Published in: Canadian Journal of Kidney Health and Disease
DOI: 10.1177/2054358119879896
Published: 01/10/2019
Document Version
Publisher's PDF, also known as Version of record
Link to publication
Citation for published version (APA):
Sukkar, L., Talbot, B., Jun, M., Dempsey, E., Walker, R., Hooi, L., Cass, A., Jardine, M., & Gallagher, M. (2019). Protocol for the Study of Heart and Renal Protection-Extended Review: Additional 5-Year Follow-up of the Australian, New Zealand, and Malaysian SHARP Cohort. Canadian Journal of Kidney Health and Disease, 6(January-December), 1-11. https://doi.org/10.1177/2054358119879896

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Download date: 20. May. 2021
Protocol for the Study of Heart and Renal Protection-Extended Review: Additional 5-Year Follow-up of the Australian, New Zealand, and Malaysian SHARP Cohort

Louisa Sukkar¹,², Ben Talbot¹, Min Jun¹, Erika Dempsey¹, Robert Walker³, Lai Hooi⁴, Alan Cass⁵, Meg Jardine¹,², and Martin Gallagher¹,² on behalf of the SHARP-ER Study Collaborators

Abstract

Background: There are limited studies on the effects of statins on outcomes in the moderate chronic kidney disease (CKD) population and their trajectory to end-stage kidney disease.

Objective: To examine the long-term effects of lipid-lowering therapy on all-cause mortality, cardiovascular morbidity, CKD progression, and socioeconomic well-being in Australian, New Zealand, and Malaysian SHARP (Study of Heart and Renal Protection) trial participants—a randomized controlled trial of a combination of simvastatin and ezetimibe, compared with placebo, for the reduction of cardiovascular events in moderate to severe CKD.

Design: Protocol for an extended prospective observational follow-up.

Setting: Australian, New Zealand, and Malaysian participating centers in patients with advanced CKD.

Patients: All SHARP trial participants alive at the final study visit.

Measurements: Primary outcomes were measured by participant self-report and verified by hospital administrative data. In addition, secondary outcomes were measured using a validated study questionnaire of health-related quality of life, a 56-item economic survey.

Methods: Participants were followed up with alternating face-to-face visits and telephone calls on a 6-monthly basis until 5 years following their final SHARP Study visit. In addition, there were 6-monthly follow-up telephone calls in between these visits. Data linkage to health registries in Australia, New Zealand, and Malaysia was also performed.

Results: The SHARP-Extended Review (SHARP-ER) cohort comprised 1136 SHARP participants with a median of 4.6 years of follow-up. Compared with all SHARP participants who originally participated in the Australian, New Zealand, and Malaysian regions, the SHARP-ER participants were younger (57.2 [48.3-66.4] vs 60.5 [50.3-70.7] years) with a lower proportion of men (61.5% vs 62.8%). There were a lower proportion of participants with hypertension (83.7% vs 85.0%) and diabetes (20.0% vs 23.5%).

Limitations: As a long-term follow-up study, the surviving cohort of SHARP-ER is a selected group of the original study participants, which may limit the generalizability of the findings.

Conclusion: The SHARP-ER study will contribute important evidence on the long-term outcomes of cholesterol-lowering therapy in patients with advanced CKD with a total of 10 years of follow-up. Novel analyses of the socioeconomic impact of CKD over time will guide resource allocation.

Trial Registration: The SHARP trial was registered at ClinicalTrials.gov NCT00125593 and ISRCTN 54137607.

Abrégé

Contexte: On trouve peu d'études faisant état de l'effet des statines sur les issues des patients atteints d'insuffisance rénale chronique (IRC) modérée et sur leur évolution vers l'insuffisance rénale terminale (IRT).

Objectif: Observer les effets à long terme d'un traitement hypolipidémiant sur la mortalité toutes causes, la morbidité cardiovasculaire, la progression de l'IRC et le mieux-être socioéconomique des participants australiens, néo-zélandais et malaysiens.

Creative Commons CC BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License (http://www.creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
malaisiens, à l’essai SHARP; un essai contrôlé à répartition aléatoire qui portait sur l’effet comparatif d’une combinaison de simvastatine et d’ézetimibe, ou d’un placebo, sur la réduction des événements cardiovasculaires en contexte d’IRC modérée à grave.

**Plan de l’étude:** Il s’agit d’un protocole pour un suivi prospectif et observationnel prolongé.

**Cadre:** Les centres d’Australie, de Nouvelle-Zélande et de Malaisie traitant des patients atteints d’IRC de stade avancé et participant à l’essai SHARP.

**Sujets:** Tous les participants à l’essai SHARP encore vivants lors de la dernière visite de l’étude.

**Mesures:** Les principaux résultats ont été mesurés par autodéclaration des participants et vérifiés auprès des données administratives de l’hôpital. Les résultats secondaires ont été mesurés à l’aide d’un questionnaire validé évaluant la qualité de vie liée à l’état de santé, une enquête économique de 56 questions.

**Méthodologie:** Les participants ont été suivis tous les six mois en alternant les visites en clinique et les entretiens téléphoniques, jusqu’à cinq ans après la dernière visite prévue lors de l’essai SHARP. On a procédé au couplage des données avec les registres de santé d’Australie, de Nouvelle-Zélande et de Malaisie.

**Résultats:** La cohorte SHARP-ER était constituée de 1 136 participants à l’essai SHARP et la durée de suivi médiane était de 4,6 ans. En comparaison de l’ensemble des patients ayant participé à l’essai SHARP en Australie, en Nouvelle-Zélande et en Malaisie, la cohorte SHARP-ER était plus jeune (57,2 [48,3-66,4] contre 60,5 [50,3-70,7] ans), comptait moins d’hommes (61,5 % contre 62,8 %) et présentait une plus faible proportion de patients hypertendus (83,7 % contre 85,0 %) ou diabétiques (20,0 % contre 23,5 %).

**Limites:** Puisqu’il s’agit d’une étude de suivi à plus long terme, la cohorte de survivants (SHARP-ER) constitue un groupe choisi à partir de l’ensemble des participants à l’essai initial, ce qui pourrait limiter la généralisabilité des résultats.

**Conclusion:** L’étude SHARP-ER, avec un suivi total sur dix ans, apportera des informations importantes sur les effets à long terme d’un traitement hypolipidémiant chez les patients atteints d’IRC de stade avancé. De nouvelles analyses des impacts socioéconomiques de l’IRC au fil du temps éclaireront l’affectation des ressources.

**Keywords**
chronic renal insufficiency, disease progression, follow-up studies, income, myocardial infarction, poverty, statins

**What was known before**

In people with moderate to severe kidney disease, over a median follow-up of 4.9 years, a combination of simvastatin and ezetimibe, compared with placebo, produced a 17% proportional reduction in major atherosclerotic events (nonfatal myocardial infarction or coronary death, nonhemorrhagic stroke, or any arterial revascularization procedure).

**What this adds**

This study aims to extend the follow-up of these individuals to assess the long-term outcomes of statin therapy as kidney disease declines. This study will also provide novel understandings of the economic burden of chronic kidney disease for patients and their families.

**Introduction**

Chronic kidney disease (CKD) is a key element of the increasing global burden of chronic diseases.¹ The increasing prevalence of CKD has been well documented,²,³ as has its association with both cardiovascular disease and premature death.⁴ Cardiovascular disease is the leading cause of death in people with CKD, and its prevalence rises with declining kidney function. Importantly, individuals with mild to moderate CKD are more likely to die from cardiovascular causes than develop end-stage kidney disease, the final stage of CKD.⁵ Despite this, there are limited data from large-scale randomized trials on treatments that can slow or halt kidney disease progression or prevent cardiovascular events.

Several randomized placebo-controlled trials have tested the effects of lowering low-density lipoprotein cholesterol

---

¹The George Institute for Global Health, Newtown, Australia
²Faculty of Medicine and Health, The University of Sydney, NSW, Australia
³Dunedin School of Medicine, University of Otago, Dunedin, New Zealand
⁴Hospital Sultanah Aminah, Johor Bahru, Malaysia
⁵Menzies School of Health Research, Casuarina, NT, Australia

**Corresponding Author:**
Martin Gallagher, The George Institute for Global Health, UNSW Sydney, P.O. Box M201, Missenden Road, NSW 2050, Australia.
Email: mgallagher@georgeinstitute.org.au
Participants aged 40 years or older with CKD (defined as at least 1 measurement of serum creatinine of at least 150 μmol/L in men or 130 μmol/L in women) with no known history of myocardial infarction and coronary revascularization were enrolled between 2003 and 2006 in 18 countries. Participants were randomized in the ratio of 4:4:1 to a combination of simvastatin and ezetimibe, matching placebo, or simvastatin 20 mg alone (Figure A1). Those allocated to simvastatin alone were re-randomized after 1 year to one of the other 2 comparison arms. After initial randomization, participants were followed up in study clinics at 2 and 6 months, and then every 6 months for at least 4 years. At each of these visits, information was recorded on all serious adverse events. A double-dummy method ensured that participants and staff remained unaware of treatment allocation. Although SHARP participants were given the option to discover their treatment after the completion of the original SHARP study, fewer than 3% of participants exercised this option in the global SHARP cohort.

SHARP Post-Trial Follow-Up

The SHARP-PTFU seeks to provide long-term follow-up of the global cohort of SHARP participants alive at the end of the SHARP trial. It will assess the primary and secondary outcomes of SHARP over an additional 5 years with participating centers using a number of methods, including post-trial questionnaires and linkage to routinely collected national data sets (eg, hospital admission data, cancer and mortality data).

As a component of SHARP-PTFU, the SHARP-ER study will contribute primary and secondary post-trial outcome data to the PTFU, with the differences in the 2 initiatives summarized in Table 1.

The SHARP-ER commenced recruitment in August 2012. All participants alive at the final SHARP study visit in participating centers in Australia, New Zealand, and Malaysia (August 2010) who were not previously documented as having withdrawn consent were eligible for inclusion in SHARP-ER. Exclusion criteria for SHARP-ER were the presence of concomitant major illness that would limit the participant’s follow-up (in the opinion of the treating physician), a high likelihood that the participant would not adhere to follow-up, and inability to provide informed consent for reasons of mental or physical incapacity.

The study was conducted in accordance with the approved study protocol, the principles of the “Declaration of Helsinki,” and the laws and regulations of the relevant countries. All participating centers obtained independent ethics approval prior to study commencement.

Methods

Design

The SHARP-ER study is a longitudinal cohort study, extending the follow-up of participants in participating centers in Australia, New Zealand, and Malaysia who were alive at the end of the SHARP trial.

SHARP Trial

Details of the recruitment of participants and the study design have been published previously.9,17 In brief, 9270 participants aged 40 years or older with CKD (defined as at least 1 measurement of serum creatinine of at least 150 μmol/L in men or 130 μmol/L in women) with no known history of myocardial infarction and coronary revascularization were enrolled between 2003 and 2006 in 18 countries. Participants were randomized in the ratio of 4:4:1 to a combination of simvastatin and ezetimibe, matching placebo, or simvastatin 20 mg alone (Figure A1). Those allocated to simvastatin alone were re-randomized after 1 year to one of the other 2 comparison arms. After initial randomization, participants were followed up in study clinics at 2 and 6 months, and then every 6 months for at least 4 years. At each of these visits, information was recorded on all serious adverse events. A double-dummy method ensured that participants and staff remained unaware of treatment allocation. Although SHARP participants were given the option to discover their treatment after the completion of the original SHARP study, fewer than 3% of participants exercised this option in the global SHARP cohort.

Study Procedures

The SHARP-ER study did not involve allocation to further study treatment. The nature of any cholesterol treatment used by participants following the end of the SHARP Study was measured by questionnaire and data linkage.
The vital status of all SHARP study participants at 18 to 24 months after their final study visit was determined through medical records, direct contact with medical staff (renal physicians and general practitioners), and death registries. Consentig participants were followed up with 3 face-to-face visits at 18 to 24 months, 3.5 years, and 5 years, followed by the final SHARP Study visit. In addition, there were 6-monthly follow-up telephone calls in between these visits (Table 2).

The data collection included the following:

- Physical signs: weight, height, and blood pressure;
- Medication usage: including the use of lipid-lowering and antiplatelet medications;
- Assessment of primary and secondary SHARP-ER study outcomes: including admissions to hospital, and requirements for chronic dialysis or kidney transplant. These outcomes were ascertained by participant self-report at telephone interview or at the individual patient visit. This was further verified using discharge summaries from the treating hospitals;

The vital status of all SHARP study participants at 18 to 24 months after their final study visit was determined through medical records, direct contact with medical staff (renal physicians and general practitioners), and death registries. Consentig participants were followed up with 3 face-to-face visits at 18 to 24 months, 3.5 years, and 5 years, followed by the final SHARP Study visit. In addition, there were 6-monthly follow-up telephone calls in between these visits (Table 2).

The data collection included the following:

- Physical signs: weight, height, and blood pressure;
- Medication usage: including the use of lipid-lowering and antiplatelet medications;
- Assessment of primary and secondary SHARP-ER study outcomes: including admissions to hospital, and requirements for chronic dialysis or kidney transplant. These outcomes were ascertained by participant self-report at telephone interview or at the individual patient visit. This was further verified using discharge summaries from the treating hospitals;

The study questionnaire was developed using questions drawn from the existing validated tools to evaluate health-related quality of life (HR-QoL)\(^4\) and the social,\(^5\) cognitive, and emotional impacts of kidney disease.\(^5\) The HR-QoL was measured through telephone interview by a central interviewer (blinded to SHARP study allocation) at the initial visit, followed by assessments at 3.5 and 5 years of follow-up. These interviews used the EuroQoL 5 dimensions questionnaire (EQ-5D) and a Health Services Usage Questionnaire. In addition, a 56-item detailed economic

| Table 1. Differences Between SHARP-ER Study and the Global SHARP-PTFU Study. |
|---------------------------------------------------------------|
| **Population** | SHARP survivors in Australia, New Zealand, and Malaysia | All SHARP survivors |
| **Outcome measures** | Face-to-face visits | Linkage to registry data |
| | Telephone interviews | |
| | Study questionnaires | |
| | Linkage to registry data | |
| **Outcomes** | Major atherosclerotic events\(^a\) | Major atherosclerotic events |
| | Major vascular events\(^b\) | Major vascular events |
| | Renal outcomes\(^c\) | Renal outcomes |
| | Socioeconomic outcomes\(^d\) | |
| **Follow-up** | 5 years | 5 years with ongoing linkages planned |

Note. SHARP = Study of Heart and Renal Protection; SHARP-ER = Study of Heart and Renal Protection-Extended Review; PTFU = Post-Trial Follow-Up
\(^a\)Major atherosclerotic events defined as coronary death, myocardial infarction, nonhemorrhagic stroke, or any revascularization procedure (excluding vascular access surgery for dialysis).
\(^b\)Major vascular events defined as hemorrhagic stroke and noncoronary death.
\(^c\)Renal outcomes defined as initiation of long-term renal replacement therapy or renal transplantation.
\(^d\)Socioeconomic outcomes will include an assessment of (1) illness-related catastrophic expenditure, (2) illness-related poverty, and (3) economic hardship.

| Table 2. Study of Heart and Renal Protection-Extended Review Study Schedule. |
|---------------------------------------------------------------|
| **Time since completion of final SHARP study visit** | **Participant enrollment (screening)** | **Visit 1 (18-24 mo)** | **Telephone call 30 mo** | **Telephone call 36 mo** | **Visit 2 (42 mo)** | **Telephone call 48 mo** | **Telephone call 54 mo** | **Visit 3 (60 mo)** |
| Prior written consent | x | x | | | | | | |
| Survival status | x | x | x | x | x | x | x | x |
| Physical signs | x | x | x | x | x | x | x | x |
| SHARP primary events (major atherosclerotic events) | x | x | x | x | x | x | x | x |
| Subsidiary study outcomes | x | x | x | x | x | x | x | x |
| Biochemistry | x | x | x | x | x | x | x | x |
| Hematology | x | x | x | x | x | x | x | x |
| Socioeconomic questionnaire | x | x | x | x | x | x | x | x |
| Registry linkage | x | x | x | x | x | x | x | x |

The study questionnaire was developed using questions drawn from the existing validated tools to evaluate health-related quality of life (HR-QoL)\(^4\) and the social,\(^5\) cognitive, and emotional impacts of kidney disease.\(^5\) The HR-QoL was measured through telephone interview by a central interviewer (blinded to SHARP study allocation) at the initial visit, followed by assessments at 3.5 and 5 years of follow-up. These interviews used the EuroQoL 5 dimensions questionnaire (EQ-5D) and a Health Services Usage Questionnaire. In addition, a 56-item detailed economic
survey was used to assess the socioeconomic impact of CKD. This included an assessment of (1) out-of-pocket expenditure on illness not covered by insurance, such as expenditure on health care, medications, investigations, and paid care; (2) economic hardship, defined as an inability to make necessary household payments, such as housing, energy, food, and health care costs, or requiring assistance to meet such costs; (3) household income in the past 12 months, measured against the median income levels obtained from National Statistical Bureau.

Where available, data linkage using registries was used as secondary ascertainment for mortality (using national death registries and Australian Institute of Health and Welfare’s National Death Index) and dialysis commencement (using renal replacement therapy [RRT] registries: the Australian and New Zealand Dialysis and Transplant Registry [ANZDATA; which captures 99% of all participants commencing RRT in Australia and New Zealand] and the Malaysian National Renal Registry). In addition, consenting participants were linked to the Medicare Benefits Schedule (MBS) and the Pharmaceutical Benefits Scheme (PBS) in Australia to evaluate the health care costs of CKD and long-term LDL cholesterol–lowering treatment.

A limited assessment of the deceased participants who were alive at SHARP study closure, but died prior to the SHARP-ER study, was also undertaken. This included date and cause of death (from death certificates), and requirement for dialysis in the period between the last assessment for the SHARP study and death.

**Study Outcomes**

The primary objective of the SHARP-ER study is to contribute to the description of the long-term effects of SHARP study treatments, as part of the larger PTFU, on MAE (coronary death, myocardial infarction, nonhemorrhagic stroke, or any revascularization procedure [excluding vascular access surgery for dialysis]) and MVE (hemorrhagic stroke and noncoronary death). An important secondary objective of the study is the long-term effects of the SHARP study treatment on rates of CKD progression, defined by initiation of long-term RRT or renal transplantation. Other secondary outcomes included cancer development (excluding nonmelanoma skin cancer) and all-cause mortality. These outcomes will be analyzed using an intention-to-treat analysis.

The SHARP-ER study also measured the economic impact of CKD on participants and households at visits 1 and 3. This included a detailed appraisal of (1) the incidence of illness-related catastrophic expenditure, assessed as out-of-pocket illness expenditure exceeding 30% of annual household income over a previous 12-month period; and (3) the incidence of economic hardship, defined as perceived economic difficulties that arise as a result of chronic illness, which alters the way people affected by illness live and manage their conditions. The economic impact of disease will be measured as a difference between visit 1 and visit 3. Economic impact will also be compared across different CKD stages, which will enable an appreciation of the changing costs and economic impact associated with disease progression.

**Statistical Analysis**

Continuous variables will be reported as means with standard deviations for variables with approximately symmetric distributions and as median and interquartile ranges (IQRs) for those with skewed distributions. Study outcomes, including economic outcomes, will be assessed according to CKD category tested by linear regression analysis and logistic, Cox, or Poisson regression analysis (to estimate odds ratios, hazard ratios, and rates, respectively, with their corresponding 95% CIs), as appropriate. Multivariable models will be constructed adjusting for baseline variables, including country of participant, sociodemographic information (age, sex, body mass index, ethnicity, income, and insurance status), laboratory measurement results (estimated glomerular filtration rate, urinary albumin measurements, hematology), and comorbid conditions (diabetes mellitus, hypertension, atrial fibrillation, cardiac failure). Interaction terms between CKD category and relevant variables will be included to test for effect modification by CKD. In all time-to-event analyses, participants will be followed from baseline until the date of the outcome, death, or study completion. Analysis of the economic outcomes will use multivariate logistic regression models analogous to previous work in this area. Statistical analyses will be performed with SAS 7.11 (SAS Institute, Cary, NC, USA) and Stata software (release 13; StataCorp, College Station, TX, USA). A 2-sided P < .05 will be considered statistically significant.

**Results**

Of the original 58 SHARP study sites in Australia, New Zealand, and Malaysia, 44 sites agreed to participate in SHARP-ER. Within these sites there were a total of 1271 participants eligible for inclusion, of whom 1136 (89.4%) were included in the final SHARP-ER cohort. A proportion who died were entered according to the SHARP study consent (Figure 1). Compared with the original SHARP participants in Australia, New Zealand, and Malaysia at the beginning of SHARP, SHARP-ER participants were younger (median age = 57.2 [IQR = 48.3-66.4] vs 60.5 [50.3-70.7]) and had a lower proportion with comorbid diabetes (20.0% vs 23.5%). All other baseline characteristics including blood pressure, renal function, and lipid profile were similar (Table 3). The
proportion of participants on RRT at the beginning of SHARP was also similar between the 2 cohorts.

**Discussion**

The SHARP trial was a large-scale randomized controlled trial, which assessed the effects of LDL lowering in patients with moderate to severe CKD. In SHARP, allocation to combination therapy with simvastatin plus ezetimibe over a median of 4.9 years reduced the incidence of MAE without an increase in any of the prespecified safety outcomes. Long-term follow-up of efficacy and safety in randomized trials of statin-based LDL-lowering therapy in other populations has demonstrated continuing benefits on vascular events and reassuring safety for nonvascular events such as cancer. While extended follow-up of patients in the 4D
(Die Deutsche Diabetes Dialyse) and Assessment of LEscol in Renal Transplantation (ALERT) trials of lipid lowering in those with CKD has been done previously, these studies only included patients on dialysis or who had undergone a renal transplant, meaning that there is a paucity of evidence for the long-term effects of LDL lowering in those with moderate to severe predialysis kidney disease.15,16

To address this issue, the SHARP-PTFU study will assess the long-term effects of lowering LDL cholesterol on first MAE, progression of renal disease, and long-term safety outcomes among surviving SHARP participants. The SHARP-ER study conducted in Australia, New Zealand, and Malaysia is part of this broader international initiative and followed surviving SHARP participants for a further 5 years with face-to-face

| Characteristic                                      | AUS/NZ/MYL SHARP participants (N = 2029) | SHARP-ER participants (N = 1136) |
|----------------------------------------------------|----------------------------------------|----------------------------------|
| Sex, No. (%)                                       |                                        |                                  |
| Men                                                | 1274 (62.8)                            | 699 (61.5)                       |
| Women                                              | 755 (37.2)                             | 437 (38.5)                       |
| Age (years) Median (IQR)                           |                                        |                                  |
| 40-49                                               | 495 (24.4)                             | 338 (29.8)                       |
| 50-59                                               | 498 (24.5)                             | 333 (29.3)                       |
| 60-69                                               | 496 (24.5)                             | 263 (23.2)                       |
| 70+                                                 | 540 (26.6)                             | 202 (17.8)                       |
| Comorbidities, No. (%)                             |                                        |                                  |
| Diabetes                                           | 477 (23.5)                             | 227 (20.0)                       |
| Hypertension                                       | 1725 (85.0)                            | 951 (83.7)                       |
| Blood pressure, mean (SD)                          |                                        |                                  |
| Systolic blood pressure, mm Hg                     | 141 (23.0)                             | 140 (23.0)                       |
| Diastolic blood pressure, mm Hg                    | 79 (13.0)                              | 80 (12.0)                        |
| Renal status, No. (%)                              |                                        |                                  |
| Not on renal replacement therapy (CKD)             | 1308 (64.5)                            | 751 (66.1)                       |
| On renal replacement therapy                       | 721 (35.5)                             | 385 (33.9)                       |
| Laboratory values                                  |                                        |                                  |
| eGFR, mL/min/1.73 m³c                               |                                        |                                  |
| 45-59                                               | 28 (2.2)                               | 21 (2.8)                         |
| 30-44                                               | 345 (26.5)                             | 211 (28.1)                       |
| 15-29                                               | 647 (49.7)                             | 372 (49.6)                       |
| <15                                                 | 283 (21.7)                             | 146 (19.5)                       |
| Albumin-to-creatinine ratio measurements, No. (%)d |                                        |                                  |
| <30 mg/g                                            | 254 (19.0)                             | 140 (18.6)                       |
| 30-300 mg/g                                         | 495 (37.1)                             | 290 (38.5)                       |
| >300 mg/g                                           | 586 (43.9)                             | 324 (43.0)                       |
| Mean lipid, mmol/L, mean (SD)e                     |                                        |                                  |
| Total cholesterol                                  | 4.9 (1.1)                              | 4.9 (1.1)                        |
| LDL                                                 | 2.8 (0.8)                              | 2.8 (0.8)                        |
| HDL                                                 | 1.0 (0.3)                              | 1.1 (0.3)                        |
| Triglycerides                                       | 2.5 (1.8)                              | 2.6 (1.7)                        |
| Country                                             |                                        |                                  |
| Australia                                           | 1043 (51.4)                            | 468 (41.2)                       |
| New Zealand                                         | 285 (14.1)                             | 133 (11.7)                       |
| Malaysia                                            | 701 (34.6)                             | 535 (47.1)                       |

Note. SHARP = Study of Heart and Renal Protection; IQR = interquartile range; CKD = chronic kidney disease; LDL = low-density lipoprotein; HDL = high-density lipoprotein; eGFR = estimated glomerular filtration rate.

*Available for all participants (n = 1136/2029).

*Systolic blood pressure was available for n = 1134/2026 participants; diastolic blood pressure was available for n = 1133/2025.

*EgFR calculated using the modified renal diet (MDRD) equation. EgFR was calculated for all participants not on renal replacement therapy with available data (n = 750/1303).

*The albumin-to-creatinine ratio was measured in milligrams of albumin and grams of creatinine; it was available for n = 754/1335.

*Lipid values were available for n = 757/1941.
visits and telephone contact at 6-monthly intervals with supplementary data linkage to administrative and health registries and benefit schemes. In addition, it has collected information to assess the social and economic impact of CKD on individuals and their household.

Extended follow-up of such a large clinical trial is important because the SHARP trial might have been too short to detect any latent carcinogenic potential of LDL lowering with simvastatin plus ezetimibe. It is also valuable in providing data on the determinants of renal disease progression, as CKD often has a gradual and slowly progressive disease course.

The linkage of the SHARP-ER follow-up to registries and administrative data sets will also enable a more detailed understanding of chronic disease, as well as facilitating hypothesis generation for future research and providing valuable data on medication use along with the uptake of guideline-recommended therapy in a population where mitigation of cardiovascular risk is of paramount importance. The information gained will help to identify the treatment gaps and ascertain the factors which predispose to their reduced uptake, aiding in more efficient health resource allocation.

The SHARP-ER study will provide detailed measurements of the economic impacts of CKD from a patient perspective. Most studies that estimate out-of-pocket costs only quantify direct costs for treatment and medications, overlooking the considerable financial burden associated with self-management, including medically related transport, home-care assistance, illness-related modifications (eg, for home dialysis setup), and assistive devices. Moreover, limited data are available, which quantify personal and household economic impact more broadly with measures such as economic hardship and financial distress. The SHARP-ER attempts to overcome these deficiencies using a patient questionnaire, at 2 time points (visits 1 and 3), which include questions pertaining to household income, financial hardships (difficulty paying utility bills, mortgage repayments), as well as direct health care costs to the individual. With data on the stage of CKD, it will permit a deeper understanding of how the financial pressures vary over the duration of this chronic disease, helping to guide future resource allocation to areas of greatest patient need.

Limitations of this cohort study include the ability to generalize the findings to the wider CKD population given that participants needed to survive to enter the post-trial long-term follow-up. Despite this, the baseline characteristics of those who survived and were eligible to enter SHARP-ER were similar to those of the original SHARP cohort in the region, suggesting the SHARP-ER cohort to be representative of the wider SHARP cohort. To minimize the burden of additional travel and potential cost, laboratory results performed as part of routine care were used in the data collection. This has limitations due to variability between laboratories regarding measuring methods and normal ranges within a country and between different countries.

**Conclusions**

In conclusion, the SHARP-ER study is the collection of detailed data for a well-characterized cohort with moderate to severe CKD. It will allow for reporting of outcomes of MAE and MVE, rates of CKD progression, rates of cancer development (excluding nonmelanoma skin cancer), and all-cause mortality, medication usage, and socioeconomic impacts. Data for many of these outcomes will be available for a 10-year period (5 years of SHARP trial data and a further 5 years of follow-up with SHARP-ER), enabling analysis of recurrence of events and an unprecedented understanding of the burden of morbidity over time.
Figure A1. SHARP trial profile.
SHARP-ER Study

Regional Coordination. The George Institute for Global Health, Sydney: A. Cass, M. Gallagher, Graham Hillis, J. Lee, E. Dempsey, A. Yianni, M. Gorzeman, S. Spratley, E. Ivanova, N. Nath Kumar, W. Ooi, B. Essue, S. Coggan, S. Decollogne, E. Fjalling

Local Clinical Center

Australia
Albury Base Hospital: R. Auwardt, P. Cogdell
Austin Health, Melbourne: P. Mount, M. Roberts, M. Veenendaal, P. Bisscheroux
Bundaberg Base Hospital: P. Miach, D. Booth, C. Arnold
Cairns Base Hospital: M. Mantha, S. Green
Central Northern Adelaide Renal and Transplantation Service (CNARTS): T. Elias, S. McDonald, M. Hockley, K. Fisher
Concord Repatriation Hospital: S. Sen, S. Hand
Core Research Group Pty Ltd, Milton: D. Colquhoun, A. Ferreira-Jardim, H. Morison, L. Williams
Fremantle Hospital: P. Ferrari, S. Swaminathan, U. Steinwandel, K. Hollmann, B. Siva
Gold Coast Hospital: E. Meagher, T. Titus, H. McEvoy, T. Schmidt, T. Chad
John Hunter Hospital, Newcastle: S. Carney, L. Garvey, A. Gillies, T. Brown, Y. Choi
Launceston General Hospital: M. Mathew, D. Cooke, S. Smith
Liverpool Hospital: M. Suranyi, G. Rayment, J. Wong, M. Wong
Nambour General Hospital: N. Gray, A. Pollock, S. Wadham
Nepean Hospital, Penrith: R. Wyndham, K. Sud, N. Ubera, P. Murie
Princess Alexandra Hospital, Woolloongabba: D. Johnson, C. Hawley, J. Sudak
Renal Research, Gosford: S. Roger, L. Bohringer
Royal Hobart Hospital: M. Jose, L. Jeffs, G. Kirkland, R. Papatriantafillou, S. Hennessy
Royal Melbourne Hospital: E. Pedagogos, M. Farrell, C. Karschimkus, M. Raspudic, N. Toussaint
Royal North Shore Hospital, St Leonards: B. Cooper, J. Pearse, A. Mather, H. Tsang, M.G. Wong, C. Weischelberger
Royal Prince Alfred Hospital, Sydney: P. Snelling, V. Bielski, S. Sherwood, A. Bisson, M. Barden
Sir Charles Gairdner Hospital, Perth: B. Hutchison, H. Herson, S. Pelicano, G. Dogra, W. Lim, D. Chan, H. Moody, N. Boudville
St Vincent’s Hospital, Fitzroy: R. Langham, K. Mullins
Sydney Adventist Hospital: P. Collett, A. Heath, J. Esplin, K. Sutherland, D. Talafua
The Canberra Hospital: G. Talaualikar, P. Johnson
Westmead Hospital: G. Rangan, P. Murie, H. Heathwood
Wollongong/Shellharbour Hospitals: M. Lonergan, M. Magill, C. Wen

Malaysia
Hospital Ipoh: C.L. Loh, Norlia K, Y.Y. Lee
Hospital Kuala Lumpur: Ghazali A., N. Baskaran, S. Bavanandam, R. Visvanathan, S.L. Wong, Rosnawati Y.
Hospital Kuala Terengganu: Zawawi N., Zaiha H, Hindu A.
Hospital Melaka: Korina R., Yunaidah A.
Hospital Pulau Pinang: L.M. Ong, Rozina G., S.A. Goh, Y.F. Liew, G.L. Teoh
Hospital Raja Perempuan Zainab II, Kota Bharu: Wan Hasnul W. H, Norhayati A., Norhayati I., Sukeri M., Zuad F.R.
Hospital Selayang: H.S. Wong, C.Y. Goh, B.C. Bee, C. Ramasamy, Rafidah A.
Hospital Sultanah Aminah, Johor Bahru: L.S. Hooi, W.J. Liu, Razali O., Haslinah S.
Hospital Taiping: I. Vaithilingam, Jaaini A., Faridah L., C.H. Lim
Hospital Tengku Ampuan Afdan: Ramli S., Rosnah A.A., C.C. Tam, Ahmad Fuad A.T., Fariz Safhan M.N.
Hospital Tengku Ampuan Rahimah, Selangor: C.C. Tan, Shahnaz F.K., Wazir H., Azura H.B.
Hospital Tuanku Jaffar ‘ar: Seremban: Lily M., Wan Shaariah M.Y., Faezah I., M.W. Lim, S. Sivathasam, Fusiah Z
Hospital Umum Sarawak: C.H.H. Tan, Javelin P., L.S. Ng, L.W.S. Hii
University Malaya Medical Center, Kuala Lumpur: S.K. Lim, K.P. Ng, L.P. Tan, T.C. Keng, Asmalina M.

New Zealand
Auckland City Hospital: J. Collins, M. Upjohn
Christchurch Hospital: D. McGregor, J. Usher
Dunedin Hospital: R. Walker, G. Ellis
Middlemore Hospital, Auckland: D. Voss, M. Upjohn

Ethics Approval and Consent to Participate
The study was conducted in accordance with the approved study protocol, the principles of the “Declaration of Helsinki”, and the laws and regulations of the relevant countries. All participating centres obtained independent ethics approval prior to study commencement.

Consent for Publication
All authors consent to the publication of this study protocol.

Availability of Data and Materials
The data and materials are not available for this study.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: SHARP was funded by Merck/Schering-Plow Pharmaceuticals (North Wales, PA), with additional support from the Australian National Health Medical Research Council, the British Heart Foundation, and the UK Medical Research Council. SHARP was initiated, conducted, and interpreted independently of the principal study funder (Merck & Co. and Schering Plow Corp., which merged in 2009). The SHARP-ER Study was supported by an Australian National Health & Medical Research Council grant (App1030973). The funding bodies did not have any role in study design, collection, analysis and interpretation of data or in the decision to submit the report for publication.

ORCID iDs
Louisa Sukkar https://orcid.org/0000-0001-7409-2938
Martin Gallagher https://orcid.org/0000-0001-9187-6187

References
1. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889): 339-352.
2. Cass AC, Gallagher MP, Howard J, McDonald S, Snelling P, White SL. The Economic Impact of End-stage Kidney Disease in Australia: Projections to 2020. Melbourne, VIC, Australia: Kidney Health Australia; 2010.
3. Australia and New Zealand Dialysis and Transplant Registry. ANZDATA Report 2013. Adelaide, SA, Australia: ANZDATA Registry; 2013.
4. Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol. 2006;17(7):2034-2047.
5. Gansevoort RT, Matushita K, van der Velde M, et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. Kidney Int. 2011;80(1):93-104.
6. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238-248.
7. Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395-1407.
8. Holdaas H, Fellstrom B, Jardine AG, et al. Effect of Fluavastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003;361(9374):2024-2031.
9. SHARP Collaborative Group. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181-2192.
10. Heart Protection Study Collaborative Group. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised controlled trial. Lancet. 2011;378(9808):2013-2020.
11. LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease). Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet. 2002;359(9315):1379-1387.
12. Lloyd SM, Slott DJ, deCraen AJ, et al. Long-term effects of Statin treatment in elderly people: extended follow-up of the prospective Study of Pravastatin in the elderly at risk (PROSPER). PLoS ONE. 2013;8(9):e72642.
13. Pedersen TR, Wilhelmsen L, Faergeman O, et al. Follow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering. Am J Cardiol. 2000;86(3):257-262.
14. Ford I, Murray H, McCowan C, Packard CJ. Long term safety and efficacy of lowering LDL cholesterol with Statin therapy: 20-year follow-up of west of Scotland coronary prevention study. Circulation. 2016;133(11):1073-1080.
15. Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Long-term cardiac outcomes in renal transplant recipients receiving Fluvastatin: the ALERT extension study. Am J Transplant. 2005;5(12):2929-2936.
16. The German Diabetes and Dialysis Study Investigators. Long-term effects following 4 years of randomized treatment with atorvastatin in patients with type 2 diabetes mellitus on hemodialysis. Kidney Int. 2016;89(6):1380-1387.
17. SHARP Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J. 2010;160(5):785-794.e10.
18. EuroQol—A new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199-208.
19. Grootaert C, Narayan D, Jones VN, Woolcock M. Measuring Social Capital: An Integrated Questionnaire (World bank working paper). Washington, DC: The World Bank; 2004.
20. Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perception questionnaire. J Psychosom Res. 2006;60(6):631-637.
21. Survey of Income and Program Participation (SIPP). Washington, DC: DUCB; 2010. http://www.census.gov/sipp/. Accessed September 20, 2016.
22. Australian Institute of Health and Welfare. National death index 2016. https://www.aihw.gov.au/about-our-data/our-data-collections/national-death-index. Accessed January 28, 2019.
23. Australian and New Zealand dialysis and transplant registry 2016. http://www.anzdata.org.au. Accessed January 28, 2019.
24. Medicare benefits schedule 2017. http://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/Content/Home. Accessed January 28, 2019.
25. Pharmaceutical benefits scheme 2016. http://www.health.gov.au/pbs. Accessed January 28, 2019.
26. De Vos K, Zaidi MA. Equivalence scale sensitivity of poverty statistics for the Member States of the European Community. Rev Income Wealth. 1997;43(3):319-333.
27. Jeon Essue B, Jan S, Wells R, Whitworth JA. Economic Hardship associated with managing chronic illness: a qualitative inquiry. BMC Health Serv Res. 2009;9:182-111.
28. Jan S, Lee SWL, Sawhney JPS, et al. Catastrophic health expenditure on acute coronary events in Asia: a prospective study. Bull World Health Organ. 2016;94(3):193-200.